BPGbio and debra of America Team Up to Advance Breakthrough Treatment for Epidermolysis Bullosa: Phase II/III Trial Set to Begin!

BPGbio Inc., an AI-powered biopharma on a mission to revolutionize biology for the benefit of humanity, has teamed up with debra of America to launch a Phase II/III clinical trial of its BPM 31510 for Epidermolysis Bullosa.

In this partnership, debra of America will lend a hand to raise awareness of the trial, provide insight and guidance for patient recruitment, and advocate for the trial. This trial is expected to kick off in the second half of the year and is sure to bring hope to those affected by this debilitating disease.

Ehlers-Danlos Syndrome (EDS) is a life-changing connective tissue disorder that affects an estimated one in every 20,000 children born in the United States. Its symptoms vary widely, ranging from mild to severe, but all cause significant decline in quality of life for those living with it. In the most extreme cases, EDS can lead to premature death due to complications such as an aggressive form of squamous cell carcinoma.

Preliminary data from the Phase 1 clinical trial of BPGbio’s BPM 31510 indicates that this innovative treatment may be a safe and effective option for improving wound healing in patients with all types of epidermolysis bullosa. Preclinical studies have revealed that BPM 31510 has the potential to positively influence the wound healing process, providing much-needed relief for EB sufferers.

We are delighted to further our collaboration with debra of America for the Phase II/III trial of our EB drug candidate, BPM 31510. This marks a significant step forward in our journey to launch the next phase of clinical development this year. Niven R. Narain, Ph.D., President and CEO of BPGbio, stated, “We are proud to be a part of this important initiative and to contribute to finding a treatment for this debilitating condition.”

Since 2017, BPGbio has been partnering with debra of America to provide scientific support and advocate for those affected by EB. With BPGbio’s expertise and innovative research platforms, their EB Drug Candidate (BPM 31510) was even granted FDA Orphan-Drug Designation, providing much needed hope for patients and families.

With promising signs of efficacy in a disease setting that is notoriously difficult for wound healing and brings immense suffering, BPGbio’s topical agent for EB brings much-needed hope for patients and their families.

Robert S. Kirsner, M.D., Ph.D., Chairman & Harvey Blank Professor in the Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, looks forward to the late-stage studies that will confirm the efficacy and safety of this agent and help reduce the burden of the disease.

We are thrilled to partner with BPBbio on their next phase of trials for EB, after witnessing the promising results of their Phase I trial. Together, we are committed to making meaningful progress that will benefit the EB community and make a positive impact on those affected by the disease. Brett Kopelan, Executive Director of debra of America and father to a 15-year-old with severe EB, shares our excitement and optimism for this new collaboration.

In January 2023, BPGbio acquired substantially all assets of BERG, LLC, including the revolutionary Interrogative Biology® Platform, a strong pipeline of over a dozen potential candidates in oncology, neurology and rare diseases and a portfolio of 400+ US and international granted and pending patents. With this, BPGbio’s EB therapeutics are set to play a major role in the company’s future.

About BPGbio, Inc.

BPGbio Inc., a cutting-edge AI-driven biopharmaceutical company in the Boston area, is revolutionizing the drug discovery process with its Interrogative Biology platform and largest non-governmental biobank with clinical annotations. By leveraging advanced AI and patient biology, BPGbio is rapidly de-risking and accelerating the development of treatments for oncology, neurology, and rare diseases.

About debra of America

Debra of America is an indispensable part of DEBRA International, a renowned global organization that strives to improve the lives of people living with Epidermolysis Bullosa (EB). Through its network of national groups, the organization works to provide support, resources, and advocacy to those affected by this rare and painful condition. With its unwavering dedication to helping those with EB, Debra of America is making a positive and lasting impact in the world.

Leave a Comment